






Quiescence versus senescence 
 
In the adult organism, most cells are arrested but they 
are not senescent. So cell cycle arrest is not a synonym 
of senescence.  Non-senescent arrest can be caused by 
withdrawal of serum growth factors and nutrients 
(Figure 1A versus B). Without growth factors, cells 
become quiescent: low metabolism, protein synthesis 
and cellular functions, no cellular size growth. Consider 
an analogy.  You are driving a car, pushing the gas 
pedal (analogous to growth stimulation). Then you 
release the gas pedal (an equivalent to serum 
withdrawal), the car decelerates and stops. This is 
quiescence, a reversible arrest.   
    
But withdrawal of growth factors is not the only way to 
arrest cell cycle. Induction of CDK inhibitors such as 
p21, p16, p57 can cause cell cycle arrest in the presence 
of serum (Figure 1C). Serum growth factors, hormones, 
high levels of nutrients and oxygen stimulate growth-
promoting pathways such as MAPK (mitogen-activated 
protein kinase) and mTOR (Target of Rapamycin) 
pathways [1,2]. (Furthermore, cancer cells have 
constitutively over-activated by mutations mTOR and 
MAPK pathways). While blocking the cell cycle, CDK 
inhibitors do not deactivate growth-promoting pathways 
such as mTOR and MAPK. In other words, while 
growth is stimulated, cell cycle is  blocked  (Figure 1C).  
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By analogy, this is like pushing the gas and hitting the 
brakes simultaneously, with an increasing force.  This is 
destructive.  
 
In theory [3,4], over-activated growth-promoting 
pathway, when the cell cycle is blocked downstream, 
must lead to cellular hypertrophy (a large cell 
morphology), pro-inflammatory and hyper-secretory 
phenotypes, cellular overactivation with a feedback 
signal-resistance and a compensatory deactivation of 
some signaling pathways.  Cellular hypertrophy will 
cause compensatory activation of lysosomes, autophagy 
(despite active mTOR) and beta-Gal-positivity.  This 
theoretical condition strikingly resembles senescence 
caused by DNA damaging agents and radiation, 
mitogenic stimuli, oncogenes and tumor suppressors [5-
9], which all induce CDK inhibitors, thus blocking the 
cell cycle despite continuous growth stimulation (Figure 
1C). Pushed by growth-stimuli, senescent cells 
simultaneously have high levels of CDK inhibitors and 
cyclins D and E [10-13]. Erroneously, it is commonly 
repeated that senescence is an “exit from the cell cycle”.  
In reality, it is an active arrest in very advanced points 
of G1, G1/S and even G2. The senescent cell is driven 
to cycle by the stuck accelerator pedal but is blocked by 
the powerful brakes.  The tension is manifested as 
pseudo-DNA-damage response, an atypical response 
without detectable DNA damage  [14],  perhaps  similar  
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to a chronic atypical response, described as DNA-
SCARS [15]. Senescent cells secrete both mitogenic 
and anti-mitogenic factors [16-27].  
 
The conflict between ‘acceleration and braking’ leads to 
inappropriate S-phase entry and, on the other hand, to 
the loss of proliferative potential (PP). PP is not 
proliferation, PP is a potential, a hidden quality of 
arrested cells. The only way to measure PP is to remove 
the brakes. For example, ectopic expression of p21 
causes arrest, which becomes irreversible after 3-4 days, 
meaning that cells cannot proliferate even after removal 
of p21 [28,29].  Loss of PP defines cellular senescence 
in cell culture, distinguishing it from reversible 
quiescence. Still this does not imply that loss of PP is a 
clinically relevant marker. 
  
Cellular senescence in vitro and in the organism 
 
In vitro, cellular senescence is defined by the loss of 
proliferative potential (PP).  Loss of PP seems to be one 
of consequences of cellular overactivation and 
correlates with cellular hypertrophy [29].  This marker 
is universal: all senescent cells - fibroblasts and 































marker. This is convenient. However, this marker is not 
the most important for organismal aging [30].  From the 
medical perspective, a single most important marker of 
cellular senescence is increased cellular functions 
(hyper-functions). At first, this statement may seem 
startling, because hyper- functions were not considered 
as markers of senescence. Or were they?  Most studies 
of senescence were performed in fibroblasts and tumor 
cells of fibroblast origin. The classic function of such 
cells is secretion. And hyper-secretory phenotype is a 
well-known marker of senescence; a marker that, by the 
way, links cellular senescence to organismal aging and 
cancer [17-22,31]. Cellular functions are tissue-specific: 
contraction for smooth muscle cells, secretion of 
lipoproteins for hepatocytes, aggregation for platelets, 
oxidative burst for neutrophils, bone resorption for 
osteoclasts and so on.  These hyper-functions lead to 
age-related diseases, such as atherosclerosis, hyper-
tension, macular degeneration, increasing the probab-
ility of organismal death [32,33].  
 
In cell culture, quiescence could be imitated by serum 
withdrawal. (Figure 2A)  Then re-stimulation leads to 
proliferation (Figure 2A, right panel). In the organism, 
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may include some (but not all) fibroblasts, 
lymphocytes, stem and satellite cells. In quiescent 
stem cells, over-activation of the mTOR pathway 
causes stem cell proliferation and exhaustion   [34-38].  
 
In the organism, “for safety”, quiescent cells could be 
put on a permanent “parking brake”: an arrest locked 
by CDK inhibitors. Perhaps, adipocytes, neurons, 
cardiomyocytes can serve as examples. In locked cells, 
stimulation increases cell functions, instead of 
proliferation. For example, adipocytes will accumulate 
fat, whereas cardiomyocytes will enlarge and 
endocrine cells will secrete. Over-stimulation can 
cause cellular hyper-functions, secondary hormone/ 
stimuli  resistance  and  even  cell  loss.  This          
chronic over-stimulation of initially quiescent cells 
could be called physiological senescence. In the   





































physiological senescence due to chronic over-
activation. 
 
Physiological senescence can be modeled in cell 
culture. Serum withdrawal arrests normal cells. Then 
these quiescent cells can be additionally put on brakes: 
a condition we named locked quiescence [39]. Then 
re-addition of serum stimulates growth in size 
(hypertrophy), senescent morphology and permanent 
loss of PP.  It was shown that differentiated cells, 
especially in the organism, are indeed locked by CDK 
inhibitors [40,41]. In theory, such cells could still be 
quiescent or senescent.  Over-stimulation of growth-
promoting pathways (such as mTOR) converts 
‘locked’ quiescence into senescence [39], a process 
that models physiological senescence. From cell 
culture models to the organism, it is stimulation of 
growth-promoting pathways rather than cell cycle 









































avoid  undesired  proliferation.  Mild  stimulation  of  such  cells  causes  functional  responses.  Excessive  stimulation  causes 
physiological senescence. 
   































Cell cycle arrest and cancer 
 
The most common introductory statement about 
senescence is that it is a barrier to cancer. However, it is 
cell cycle arrest that is a barrier to cancer. In fact, 
avoidance of arrest is a common alteration in cancer. 
And an even more common alteration is the activation 
of growth-promoting pathways such as MAPK and 
mTOR, which are involved in the senescent phenotype. 
Activation of MAPK and mTOR makes cancer cells 
pro-senescent:  it is sufficient to impose cycle arrest in 
order to reveal the senescent phenotype. The pro-
senescent phenotype due to overactivation of MAPK 
and PI3K/mTOR can be linked to hallmarks of cancer 
such as angiogenesis, apoptosis-avoidance, Warburg 
effect, invasion and metastasis (I will discuss this in 
forthcoming reviews). If so, then the pro-senescent 
phenotype determines 4 out of 6 hallmarks of cancer 
(see 6 hallmarks of cancer by Hanahan and Weinberg 
[42]. Therefore, cancer depends on both the pro-
senescent phenotype and the disabled cell cycle control. 
I suggest that cell cycle arrest typically leads to 

































state  (over-activation  of  mTOR-centric  network)  and 
cell cycle arrest simply allows its manifestation. 
 
Tumor suppressors, gerosuppressors and gerosup-
pressants 
 
Some tumor-suppressors (TS) such as Rb and p16 cause 
cell cycle arrest. Other TS such as  PTEN and TSC1/2 
inhibit the growth-promoting mTOR pathway, which is 
involved in the pro-senescent phenotype. An ultimate 
tumor suppressor would have both activities: (a) cause 
arrest (which is a barrier in cancer) and (b) suppress the 
pro-senescent phenotype. In fact, such a tumor-
suppressor is p53 [43-50]. Suppression of the senescent 
phenotype by p53 may be in part explained by the 
inhibition of mTOR and hyper-metabolism by p53 [51-
59]. The notion that p53 suppresses senescence may 
also explain life extension by p53 [60]. (Note: Deletion 
of senescence-suppressing TS such as PTEN, TSC1/2 
and VHL can lead to premature senescence. In 
comparison, deletion of p53 bypass the senescence, 
because loss of p53 simultaneously abrogates cell cycle 





(B)  Gerossuppressants  do  not  abrogate  arrest  but  suppress  the  senescent  phenotype  converting  senescence  in  locked 
quiescence. 
   





























cells. I will address this topic in detail in my future 
reviews).  
 
Similarly, rapamycin suppresses the senescent 
phenotype. In cells arrested by p21, rapamycin 
decelerates the conversion from locked quiescence to 
senescence. Thus, rapamycin and other inhibitors of 
mTOR can preserve PP in p21-arrested cells [13,29,61-
63]. Please do not misunderstand this as the abrogation 
of cycle arrest and cancer-promotion. The terms 
proliferation and proliferative potential (PP) should not 
be confused. Rapamycin does not decrease p21, does 
not prevent cell cycle arrest caused by p21, does not 
‘unlock’ cells, does not force cells to proliferate, of 
course.  In contrast, it can inhibit proliferation on its 
own. But in p21-arrested cells, rapamycin can preserve 
the potential to proliferate (PP). Only when p21 and 
rapamycin are removed, the potential can be 
determined. Rapamycin does not “suppress” cell cycle 
arrest. Rapamycin delays the conversion of arrest into 
senescence. In some cell types, rapamycin can cause 
cell cycle arrest. But while inhibiting proliferation, 
rapamycin preserves PP.   
 
I put emphasis on the preservation of PP  by  rapamycin 






























hyper-secretory phenotype, which rapamycin also 
inhibits), simply because PP is viewed as a definitive 
marker of senescence. Therefore, rapamycin is a 
gerosuppressant by the current definition of cellular 
senescence  [64].  However,  it  is  suppression  of  other 
markers of senescent phenotype such as hyper-secretion 
and other hyper-functions that are most clinically 
relevant. 
 
By simultaneously suppressing the senescent phenotype 
and causing arrest, rapamycin can be viewed as an 
ultimate tumor-suppressant. In fact, the hyper-secretory, 
pro-inflammatory, pro-angiogenic phenotype are 
markers of both senescence and cancer.  I suggest that 
the cancer-preventive effect of rapamycin [65] is not 
because (or not only because) of cell cycle arrest but 
because of suppression of the senescent phenotype, 
especially in normal cells. 
 
CONCLUSIONS   
 
Cell cycle arrest (the good half) is only a part of the 
equation of senescence. The second part is growth 
stimulation, which actually causes the senescent 
phenotype (the bad half). While cell cycle arrest is a 
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extends the notion that the secretory phenotype 
contributes to cancer and that cancer and aging have a 
lot in common [22,66-68].   Furthermore, I suggest that 
all hallmarks of senescence together, especially an 
increase in tissue-specific cellular functions, caused by 
cellular over-stimulation lead to all age-related diseases 
(organismal aging) (Figure 4).   
 
So cell cycle arrest is not senescence. In cell culture, 
cell cycle arrest typically leads to senescence, because 
the cell is over-stimulated by serum, nutrients, 
oncogenes and so on. Therefore, cell cycle arrest is 
sufficient to cause senescence, especially in cancer 
cells. This is why arrest of cell cycle is semi-
coincidentally confused with senescence. Senescent 
phenotype can be dissociated from cycle arrest. And 
gerosuppressants can suppress the senescent phenotype 





I thank Pasha Apontes, Judith Campisi, Jay Caplan, 
Ronald DePinho, Boyi Gan, Jihye  Paik, Tatiana 
Pospelova, Manuel Serrano and David Stipp for critical 
reading of the manuscript. Note on the car analogy of 
aging: Several readers familiar with my previous 
publications pointed out that the gas-brakes analogy of 
cellular senescence seemingly disagree with an analogy 
of organismal aging as “speeding car without brakes” 
[33].  Two analogies are unrelated. Here, I refer to 
brakes of the cell cycle. In describing the origin of 
aging, I referred to “brakes” of the TOR-centered 
developmental program, which is not switched off     
upon its completion, thus causing aging.   To make the 
analogy precise, I would revise the title of the previous 
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